Updated results of the SOFT and TEXT trial suggest that adding ovarian suppression to exemestane or tamoxifen could improve survival outcomes.
For this phase 1b study, researchers enrolled 57 patients with ERBB2/HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.
Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.
The effectiveness of trastuzumab in retreating patients with recurrence who received it during perioperative therapy is the focus of a new study.
There are benefits and drawbacks to the public availability to DTC mutation tests.
New findings bolster the case for the predictive utility of ARID1A mutations.
Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage DiagnosisJune 19, 2018
A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.
Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for InhibitionJune 18, 2018
Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.
Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.
Assignment to 6 months of adjuvant trastuzumab was non-inferior to 12 months trastuzumab in women with HER2-positive, early breast cancer.
Endocrine Therapy Alone Is Not Inferior to Chemoendocrine Therapy in Breast Cancer With Oncotype DX Scores Between 11 and 26June 03, 2018
The effect of combination chemotherapy and endocrine therapy has not been fully clarified among patients with Oncotype DX recurrence scores 11-25.
MONALEESA 3: Ribociclib Provides Significant PFS in Postmenopausal Women With ER+/HER- Advanced Breast Cancer Regardless of Prior Endocrine TherapyJune 03, 2018
With a greater than 40% decreased risk for disease progression, the combination of ribociclib and fulvestrant was significantly better than that of placebo and fulvestrant for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer.
It is important to understand mechanisms of resistance with these inhibitors to determine future treatment strategies.
SANDPIPER: First Trial to Show Modest Benefit of Taselisib in Postmenopausal Women With ER+/HER- Advanced Breast CancerJune 03, 2018
Despite modest improvements in progression-free survival, patients experienced considerable side effects with the addition of taselisib.
Researchers assigned patients with various types of relapsed/refractory cancer to receive escalating doses of JTX-2011 alone or plus nivolumab.
Although progression-free survival was not significantly increased, long-term overall survival may be improved with pertuzumab.
Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.
Computer analysis is not better than human clinical evaluation when it comes to measuring breast densityMay 23, 2018
In the United States, the standard for monitoring breast density is through the Breast Imaging Reporting and Data System (BI-RADS). There has been recent concern regarding the reproducibility of this system, as there is subjectivity in the breast density estimated by radiologists.
While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.
Understanding various factors associated with unemployment may help to guide breast cancer management to increase the rate of returning to work.
Researchers determined that there was a significant association between overall survival and adjuvant RT when factoring in CTC status.
A new technology is being developed by Caris Life Sciences to help improve the understanding of aberrant modulations that drive cancer.
Researchers are hotly pursuing 2 distinct biological paths that show remarkable promise in the hunt for an effective anticancer vaccine.
Higher ERDP scores were significantly associated with developing breast cancer.
It was unknown whether breast cancer treatment plays a causal role in the onset of diabetes.
It was suggested that estrogen alone may have a protective effect, decreasing the risk of breast cancer by 8% with every year of use.
A previous analysis showed that APBI had non-inferior efficacy.
Preventive treatments are strongly recommended in women with AH and LCIS.
Many HIV-associated cancers develop with the help of oncoviruses — some of which are sexually transmitted.
At the time of final analysis, 192 of 302 patients had died.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- FDA Approves Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
- Aggressive Follow-Up Imaging in Breast Cancer Is Geography-Specific
- Massage and Cancer
- Pembrolizumab May Lead to Favorable Long-Term Outcomes in Head and Neck Cancer
- Biomarker-Based Blood Test May Extend Reach of CT Screening for Certain Lung Cancers